Page last updated: 2024-11-04

3-phosphoglycerate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-phosphoglycerate : An organic anion obtained by deprotonation of at least one of the acidic groups of 3-phosphoglyceric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID724
CHEMBL ID87788
CHEBI ID17050
SCHEMBL ID27482
MeSH IDM0046496

Synonyms (34)

Synonym
CHEMBL87788 ,
dl-glycerate 3-phosphate
3-(dihydrogen phosphate)glyceric acid
glycerate 3-phosphates
3-(dihydrogen phosphate)glycerate
2-hydroxy-3-(phosphonooxy)propanoic acid
CHEBI:17050 ,
glyceric acid 3-phosphate
C00597
820-11-1
3-phosphoglycerate
G3P ,
glycerate 3-phosphate
glyceric acid-3-phosphate
76C0138A-0EA9-4A51-B2C9-BAEC6DE64355
2-hydroxy-3-phosphonooxypropanoic acid
2-oxidanyl-3-phosphonooxy-propanoic acid
A841756
propanoic acid, 2-hydroxy-3-(phosphonooxy)-
SCHEMBL27482
3-phospho-glyceric acid
3-glycerophosphoric acid
glycerate-3-p
3-p-glycerate
3-pg
3-pga
3-glycerophosphorate
3-phospho-glycerate
Q32904835
DTXSID601002368
HY-113491
CS-0062388
bdbm50469695
AKOS040744141

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" So far, in spite of achieving a considerable increase in PEPC levels, more work needs to be done with respect to the correct dosage and location before that goal is reached."( Manipulating PEPC levels in plants.
Gerentes, D; Gousset-Dupont, A; Hodges, M; Jeanneau, M; Lebouteiller, B; Perez, P; Vidal, J, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monophosphoglyceric acidA glyceric acid phosphate in which only one of the hydroxy groups has been phosphorylated.
tetronic acid derivativeAn aldonic acid derivative that is formally obtained from a tetronic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (67)

PathwayProteinsCompounds
Glycine and Serine Metabolism2452
Glycolysis1423
Gluconeogenesis2232
Glycerolipid Metabolism1124
Starch and Sucrose Metabolism1626
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Glycerol Kinase Deficiency1124
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
Non-Ketotic Hyperglycinemia2452
Hyperglycinemia, Non-Ketotic2452
D-Glyceric Acidura1124
Familial Lipoprotein Lipase Deficiency1124
Glycogenosis, Type VII. Tarui Disease1423
Glycogen Synthetase Deficiency1626
Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis1626
Glycogenosis, Type IV. Amylopectinosis, Anderson Disease1626
Glycogenosis, Type VI. Hers Disease1626
Mucopolysaccharidosis VII. Sly Syndrome1626
Sucrase-Isomaltase Deficiency1626
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Fanconi-Bickel Syndrome1423
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
3-Phosphoglycerate Dehydrogenase Deficiency2452
Glycolysis and Pyruvate Dehydrogenase2428
Cysteine Biosynthesis1329
Serine Biosynthesis and Metabolism1020
Gluconeogenesis from L-Malic Acid2024
Glycolate and Glyoxylate Degradation1522
Fructose Metabolism1520
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
Secondary Metabolites: Cysteine Biosynthesis from Serine720
Glycolate and Glyoxylate Degradation II1221
Glycolysis I1023
Glycine Metabolism1127
Serine Metabolism1025
Ethanol Fermentation1527
Photosynthesis6324
Calvin-Benson Cycle1321
Aerobic glycolysis020
Amino acid metabolism in triple-negative breast cancer cells016
Metabolic pathways of fibroblasts1718
Warburg effect modulated by deubiquitinating enzymes and their substrates011
Metabolic Epileptic Disorders2589
Carbon assimilation C4 pathway030
Hexoses metabolism in proximal tubules016
Glycolysis010
Serine biosynthesis06
Primary carbon metabolism2330
Calvin cycle1013
Photosynthetic carbon reduction014
AtMetExpress overview0109
Glycolysis and Gluconeogenesis08
Trans-sulfuration and one-carbon metabolism020
Cori cycle121
Trans-sulfuration, one-carbon metabolism and related pathways053
Biochemical pathways: part I0466
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017

Research

Studies (307)

TimeframeStudies, This Drug (%)All Drugs %
pre-199088 (28.66)18.7374
1990's81 (26.38)18.2507
2000's65 (21.17)29.6817
2010's61 (19.87)24.3611
2020's12 (3.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.52 (24.57)
Research Supply Index5.75 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index95.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (1.92%)6.00%
Case Studies2 (0.64%)4.05%
Observational0 (0.00%)0.25%
Other305 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]